The authorship of this article should be correctly ordered to protect the right ownership of this paper. In addition, Dr. Li-Long Pan has contributed significantly to this study, such that Dr. Pan should be the co-corresponding author in this study. The authorship order should be considered as follows:
Wei Wang1*, Zheng-Zhu Zhang2*, Yan Wu1, Ru-Qing Wang1, Jin-Wu Chen1, Jing Chen1, Yan Zhang1, Ya-Jun Chen1, Ming Geng1, Zhong-Dong Xu1, Min Dai3, Jin-Hua Li1 and Li-Long Pan4*
1School of Life Science, Hefei Normal University, Hefei, China.
2State Key Laboratory of Tea Plant Biology and Utilization, Anhui Agricultural University, Hefei, China.
3Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui Key Laboratory for Research and Development of Traditional Chinese Medicine, School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
4School of Medicine, Jiangnan University, Wuxi, China.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Author contributions
WW and Z-ZZ designed the experiments. WW, YW, R-QW, JC, J-WC, YZ, Y-JC, MG, Z-DX, and L-LP performed the experiments. WW, Z-ZZ, and L-LP performed the data analysis. MD, J-HL, WW, and L-LP wrote the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
(-)-Epigallocatechin-3-gallate, tetratricopeptide repeat domain protein 39B, atherosclerosis, inflammation, dyslipidemia
Citation
Wang W, Zhang Z-Z, Wu Y, Wang R-Q, Chen J-W, Chen J, Zhang Y, Chen Y-J, Geng M, Xu Z-D, Dai M, Li J-H and Pan L-L (2018) Corrigendum: (-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B. Front. Pharmacol. 9:459. doi: 10.3389/fphar.2018.00459
Received
22 March 2018
Accepted
18 April 2018
Published
01 May 2018
Volume
9 - 2018
Edited and reviewed by
Wenliang Song, Vanderbilt University Medical Center, United States
Updates
Copyright
© 2018 Wang, Zhang, Wu, Wang, Chen, Chen, Zhang, Chen, Geng, Xu, Dai, Li and Pan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wei Wang wangwei_sir@126.comZheng-Zhu Zhang zzz@ahau.edu.cnLi-Long Pan llpan@jiangnan.edu.cn
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.